Answers are grounded in this paper and cite their sources.
Examines antibody responses in Guillain-Barré Syndrome to improve treatment options.
Introduction Campylobacter jejuni is a leading cause of bacterial gastroenteritis worldwide, and a majority of isolates express an outer layer of lipooligosaccharides (LOS) that mimic human gangliosides. In approximately 1:1,000 cases of C. jejuni infection, there is a breakdown of self-tolerance resulting in antibody generation against the LOS mimics that cross-react with gangliosides found abundantly on human neurons. Opsonized neurons are then destroyed via complement and phagocyte recruitment, leading to the autoimmune paralysis known as Guillain-Barré syndrome (GBS). Our lab has observed a subset of former GBS patients possess high levels of circulating anti-ganglioside IgG one decade after recovery. Methods Serum was collected from GBS patients (acute phase and post-GBS), C. jejuni-only enteritis patients, and healthy donors. We then assessed anti-ganglioside responses via ELISA. Additionally, immune responses were analyzed by western blotting and opsonophagocytosis assays using C. jejuni-expressing ganglioside-mimicking LOS. IgG glycosylation was analyzed via liquid chromatography-mass spectrometry (LC-MS). Results Circulating anti-GM1 antibodies were observed in 10% of GBS recovered donors, 3% of healthy donors, and 0% of enteritis donors. Anti-GM1 positive sera cross-reacted with GM1-mimicking LOS and significantly killed C. jejuni at higher levels than anti-GM1 negative sera. LC-MS analyses indicate a shift towards anti-inflammatory carbohydrate modifications on IgG in the recovered donors. Conclusion Through understanding the differences in immune responses in acute-phase versus recovered GBS patients, improved therapeutics for GBS treatment can be developed.
No takes yet. Share an insight, caveat, or question.
Rogers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: